Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MIRA

Mira Pharmaceuticals Inc

Sep 06 • 04:00PM ET

1.55

Dollar change -0.03
Percentage change -1.90	%

Healthcare • Drug Manufacturers - General • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.84	Insider Own	32.64%	Shs Outstand	14.78M	Perf Week	-17.11%
Market Cap	22.91M	Forward P/E	-	EPS next Y	-0.57	Insider Trans	-3.81%	Shs Float	9.96M	Perf Month	-27.23%
Income	-12.78M	PEG	-	EPS next Q	-0.15	Inst Own	4.82%	Short Float	3.74%	Perf Quarter	101.04%
Sales	0.00M	P/S	-	EPS this Y	15.62%	Inst Trans	-	Short Ratio	0.07	Perf Half Y	63.18%
Book/sh	0.15	P/B	10.33	EPS next Y	-4.94%	ROA	-373.77%	Short Interest	0.37M	Perf Year	-73.41%
Cash/sh	0.19	P/C	8.12	EPS next 5Y	-	ROE	-748.59%	52W Range	0.51 - 6.48	Perf YTD	47.62%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-576.14%	52W High	-76.08%	Beta	4.42
Dividend TTM	-	Quick Ratio	3.68	Sales past 5Y	0.00%	Gross Margin	-	52W Low	203.92%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	3.68	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	43.24	Volatility	8.76% 10.90%
Employees	3	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	11.67
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-33.49%	Payout	-	Rel Volume	0.04	Prev Close	1.58
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Aug 28	Avg Volume	5.60M	Price	1.55
SMA20	-18.87%	SMA50	-6.38%	SMA200	17.09%	Trades		Volume	210,235	Change	-1.90%

Aug-26-24 08:00AM	MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study (ACCESSWIRE) +14.05%
Aug-19-24 07:30AM	MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End (ACCESSWIRE) -7.77%
Aug-12-24 08:30AM	Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman (GlobeNewswire)
08:00AM	MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor (ACCESSWIRE)
Aug-05-24 09:40AM	PayPal, Kellanova upgraded: Wall Street's top analyst calls (The Fly)
03:24PM	Loading…
Jul-25-24 03:24PM	Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data (Benzinga) +28.81%
07:00AM	MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action (ACCESSWIRE)
Jul-22-24 12:56PM	Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today? (InvestorPlace) +627.35%
10:31AM	Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders (Benzinga)
08:00AM	MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance (ACCESSWIRE)
Jul-15-24 07:00AM	Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC (ACCESSWIRE) +25.59%
Jun-24-24 08:30AM	MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing (PR Newswire)
Jun-10-24 08:30AM	Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year (PR Newswire)
May-29-24 08:45AM	Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance (PR Newswire)
May-21-24 08:45AM	MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog (PR Newswire) +20.00%
08:00AM	Loading…
May-20-24 08:00AM	Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog (PR Newswire) +29.77%
May-13-24 09:53PM	MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace)
Apr-02-24 08:00AM	Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission (PR Newswire)
Apr-01-24 02:53PM	MIRA Stock Earnings: Mira Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
Mar-21-24 11:04AM	MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor (PR Newswire)
Mar-08-24 08:19AM	Why Is Mira Pharmaceuticals (MIRA) Stock Up 52% Today? (InvestorPlace) +65.28%
Feb-05-24 08:30AM	MIRA Pharmaceuticals Provides Corporate Update (PR Newswire) +45.99%
Dec-04-23 08:00AM	MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations (PR Newswire) -5.26%
Nov-29-23 08:00AM	MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80% (PR Newswire)
Nov-21-23 10:42AM	MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time (PR Newswire) -16.13%
10:09AM	MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a (PR Newswire)
Nov-20-23 08:00AM	MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2 (PR Newswire) +40.06%
Oct-26-23 07:23AM	MIRA: Developing Cannabis with Benefits and Without Side Effects (Zacks) +5.38%
Sep-18-23 08:30AM	MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot (PR Newswire) +38.80%
Sep-05-23 08:31AM	MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts (PR Newswire)
08:31AM	Loading…
Aug-31-23 08:31AM	MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit (PR Newswire)
Aug-29-23 11:39AM	MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time (PR Newswire)
Aug-09-23 09:35AM	MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast (ACCESSWIRE)
Aug-03-23 02:40PM	MIRA Pharmaceuticals debuts on the Nasdaq with plans to revolutionize medicinal CBD and THC (News Direct)

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company engages in developing its product candidate, MIRA1a, as a synthetic cannabinoid analog for treating anxiety & chronic pain by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors. MIRA Pharmaceuticals was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brian McNulty	affiliate	Sep 04 '24	Proposed Sale	1.80	10,000	18,000		Sep 04 08:20 PM
McNulty Brian Patrick	10% Owner	Aug 28 '24	Sale	1.96	200,000	392,000	2,540,270	Aug 30 04:05 PM
Aminov Erez	Chief Executive Officer	May 21 '24	Buy	0.94	8,700	8,176	382,200	May 22 05:42 PM
McNulty Brian Patrick	10% Owner	Dec 04 '23	Sale	3.98	61,331	244,097	723,062	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Nov 20 '23	Sale	5.07	26,733	135,523	765,681	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Dec 06 '23	Sale	2.95	27,733	81,785	709,196	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Dec 11 '23	Sale	1.55	46,005	71,496	660,000	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Dec 07 '23	Sale	1.89	33,333	63,156	692,529	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Dec 08 '23	Sale	1.61	19,053	30,633	683,002	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Nov 29 '23	Sale	3.98	7,399	29,445	756,149	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Nov 27 '23	Sale	4.00	6,425	25,715	759,969	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Nov 21 '23	Sale	5.00	5,000	25,000	763,181	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Nov 30 '23	Sale	3.77	4,842	18,273	753,728	Dec 27 05:33 PM
McNulty Brian Patrick	10% Owner	Nov 28 '23	Sale	4.00	241	964	759,849	Dec 27 05:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MIRA

Mira Pharmaceuticals Inc

Upgrade your FINVIZ experience